Frost & Sullivan, in collaboration with the Chinese Stroke Association, released the 'White Paper on the Current Situation and Development of China's Cerebrovascular Disease Industry' (with full text available for download)

This white paper identifies 30 clinical pain points with the highest value for innovation and translation through in-depth research conducted with clinical experts in the field of cerebrovascular diseases. The aim is to provide valuable references for industry, academia, and research institutions in their selection of medical innovation directions in the field of cerebrovascular diseases. The research approach constructed in this white paper is as follows:

• Conducting field research to gather clinical needs in the field of cerebrovascular diseasesThis white paper relies on the 31 branch institutions under the Chinese Stroke Association to carry out extensive demand research activities targeting frontline healthcare workers in the field of cerebrovascular diseases. As of January 26, 2024, the white paper compilation team has received a total of positive feedback from 181 frontline healthcare workers, obtaining 1,127 clinical needs covering the entire process of cerebrovascular disease diagnosis and treatment.

   

• Gather experts' wisdom to jointly discuss clinical pain points in the field of cerebrovascular diseasesThis white paper starts from the pathophysiological characteristics of cerebrovascular diseases and comprehensively and systematically sorts out the diagnosis and treatment concepts, methods, and processes related to the disease. Guided by the diagnosis and treatment methods and processes, it arranges 1,127 clinical needs collected through first-line research. Ultimately, relying on the China Stroke Association, which brings together industry-influential clinical experts, industrial think tanks, and business leaders in various professional fields of cerebrovascular diseases, a total of 30 clinical pain points with the greatest innovative transformation value were selected from the 1,127 clinical needs.

   

• Sketching the Global Innovative Development Landscape of Cerebrovascular Diseases around Clinical Pain PointsThis white paper centers on clinical pain points and presents a three-dimensional overview of global innovative solutions in the field of cerebrovascular diseases from five directions: drugs, surgery, diagnostics, imaging, and rehabilitation. It delves into product technology, industry patterns, and development trends in each direction. The aim is to systematically depict an innovation map of cerebrovascular diseases, reveal clinical needs that cannot be met in the short term, and provide important references for the innovative development of China's cerebrovascular disease industry.

   

• Envisioning a Dreamy Future of Frontier Technologies Based on Unmet Clinical NeedsThe white paper starts from the clinical needs that are still not met in the short term and explores basic discipline research and interdisciplinary technology applications. It aims to inspire the Chinese industrial and academic communities with unlimited possibilities for breakthrough and disruptive solutions provided by cutting-edge science and technology in the field of cerebrovascular diseases, thereby fostering new technological achievements with high clinical value.

As an authoritative research report in the field of cerebrovascular diseases, the White Paper covers a wide and comprehensive range of topics. It delves into the current clinical status and future development trends from prevention, diagnosis, treatment to rehabilitation. It provides important references and guidance for the prevention, diagnosis, and treatment of cerebrovascular diseases. The content includes:

• Drug directionExploring new thrombolytic, antiplatelet, anticoagulant, lipid-lowering, blood pressure-lowering, hypoglycemic, and brain cell-protective drugs aims to optimize the treatment of acute ischemic stroke and reduce the risk of recurrence.

   

• Surgery and Interventional RadiologyPay attention to the application of innovative interventional devices, vascular interventional surgical robots, and minimally invasive surgeries to enhance the safety and effectiveness of treatment.

   

• Image directionUtilize real-time 3D-DSA, mobile imaging equipment, and advanced algorithms to optimize the diagnostic process and image quality.

   

• Inspection directionExplore cost-effective and sensitive biomarkers to assist in clinical treatment decision-making and rehabilitation plan formulation.

   

• Rehabilitation directionEmphasizing the importance of early rehabilitation, integrating digitalization, long-term monitoring, and new technology rehabilitation devices, exploring the application of neuromodulation techniques and brain-computer interfaces, aiming to improve patient rehabilitation outcomes.

The 'White Paper' summarizes the insights of 11 authoritative experts in the field of cerebrovascular disease who are engaged in interdisciplinary work between medicine and engineering, from the perspectives of cerebrovascular disease drug development, interventional therapy, surgical robots, neuroimaging, laboratory diagnostics, rehabilitation therapy, to the integration of medical technology with industry. For more content, please refer to the full report.

During the writing process, the 'White Paper' received meticulous guidance and valuable advice from many authoritative experts in the field of cerebrovascular diseases. The writing team expresses its deepest gratitude to all the experts who participated in providing guidance.

Looking ahead, we recognize that the field of cerebrovascular diseases is a dynamically developing discipline with new discoveries and treatment methods emerging continuously. To ensure that the White Paper continues to provide cutting-edge information and analysis, we plan to regularly update the White Paper in the future. We believe that through regular updates of the White Paper, we can better serve society, provide a scientific basis for the prevention, treatment, and rehabilitation of cerebrovascular diseases, offer references for the formulation of relevant policies, and also provide education and guidance for patients and the public. We look forward to collaborating with more professionals in future updates to jointly witness and document the development and progress of the cerebrovascular disease industry in China and globally.